FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003893050> ?p ?o ?g. }

• W3003893050 endingPage "e0227458" @default.
• W3003893050 startingPage "e0227458" @default.
• W3003893050 abstract "Introduction Warfarin is the most commonly prescribed oral anticoagulant in sub-Saharan Africa and requires ongoing monitoring. The burden of both infectious diseases and non-communicable diseases is high and medicines used to treat comorbidities may interact with warfarin. We describe service provision, patient characteristics, and anticoagulation control at selected anticoagulation clinics in Uganda and South Africa. Methods We evaluated two outpatient anticoagulation services in Kampala, Uganda and three in Cape Town, South Africa between 1 January and 31 July 2018. We collected information from key staff members about the clinics’ service provision and extracted demographic and clinical data from a sample of patients’ clinic records. We calculated time in therapeutic range (TTR) over the most recent 3-month period using the Rosendaal interpolation method. Results We included three tertiary level, one secondary level and one primary level anticoagulation service, seeing between 30 and 800 patients per month. Care was rendered by nurses, medical officers, and specialists. All healthcare facilities had on-site pharmacies; laboratory INR testing was off-site at two. Three clinics used warfarin dose-adjustment protocols; these were not validated for local use. We reviewed 229 patient clinical records. Most common indications for warfarin were venous thrombo-embolism in 112/229 (49%), atrial fibrillation in 74/229 (32%) and valvular heart disease in 30/229 (13%). Patients were generally followed up monthly. HIV prevalence was 20% and 5% at Ugandan and South African clinics respectively. Cardiovascular comorbidity predominated. Furosemide, paracetamol, enalapril, simvastatin, and tramadol were the most common concomitant drugs. Anticoagulation control was poor at all included clinics with median TTR of 41% (interquartile range 14% to 69%). Conclusions TTR was suboptimal at all included sites, despite frequent patient follow-up. Strategies to improve INR control in sub-Saharan patients taking warfarin are needed. Locally validated warfarin dosing algorithms in Uganda and South Africa may improve INR control." @default.
• W3003893050 created "2020-02-07" @default.
• W3003893050 creator A5000645404 @default.
• W3003893050 creator A5006847944 @default.
• W3003893050 creator A5007109117 @default.
• W3003893050 creator A5036802370 @default.
• W3003893050 creator A5044865980 @default.
• W3003893050 creator A5047661674 @default.
• W3003893050 creator A5055927583 @default.
• W3003893050 creator A5059187210 @default.
• W3003893050 creator A5061991607 @default.
• W3003893050 creator A5068703662 @default.
• W3003893050 creator A5078900188 @default.
• W3003893050 creator A5081855852 @default.
• W3003893050 creator A5086632008 @default.
• W3003893050 creator A5090756265 @default.
• W3003893050 date "2020-01-29" @default.
• W3003893050 modified "2023-10-17" @default.
• W3003893050 title "A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa" @default.
• W3003893050 cites W1563471406 @default.
• W3003893050 cites W1586488555 @default.
• W3003893050 cites W1871158536 @default.
• W3003893050 cites W2035822708 @default.
• W3003893050 cites W2090697855 @default.
• W3003893050 cites W2097854437 @default.
• W3003893050 cites W2107167967 @default.
• W3003893050 cites W2120064023 @default.
• W3003893050 cites W2126780656 @default.
• W3003893050 cites W2136489990 @default.
• W3003893050 cites W2148476745 @default.
• W3003893050 cites W2151234419 @default.
• W3003893050 cites W2153326621 @default.
• W3003893050 cites W2157839219 @default.
• W3003893050 cites W2165675661 @default.
• W3003893050 cites W2363815377 @default.
• W3003893050 cites W2410566890 @default.
• W3003893050 cites W2412302878 @default.
• W3003893050 cites W2780382937 @default.
• W3003893050 cites W2803436921 @default.
• W3003893050 doi "https://doi.org/10.1371/journal.pone.0227458" @default.
• W3003893050 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6988943" @default.
• W3003893050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31995565" @default.
• W3003893050 hasPublicationYear "2020" @default.
• W3003893050 type Work @default.
• W3003893050 sameAs 3003893050 @default.
• W3003893050 citedByCount "21" @default.
• W3003893050 countsByYear W30038930502020 @default.
• W3003893050 countsByYear W30038930502021 @default.
• W3003893050 countsByYear W30038930502022 @default.
• W3003893050 countsByYear W30038930502023 @default.
• W3003893050 crossrefType "journal-article" @default.
• W3003893050 hasAuthorship W3003893050A5000645404 @default.
• W3003893050 hasAuthorship W3003893050A5006847944 @default.
• W3003893050 hasAuthorship W3003893050A5007109117 @default.
• W3003893050 hasAuthorship W3003893050A5036802370 @default.
• W3003893050 hasAuthorship W3003893050A5044865980 @default.
• W3003893050 hasAuthorship W3003893050A5047661674 @default.
• W3003893050 hasAuthorship W3003893050A5055927583 @default.
• W3003893050 hasAuthorship W3003893050A5059187210 @default.
• W3003893050 hasAuthorship W3003893050A5061991607 @default.
• W3003893050 hasAuthorship W3003893050A5068703662 @default.
• W3003893050 hasAuthorship W3003893050A5078900188 @default.
• W3003893050 hasAuthorship W3003893050A5081855852 @default.
• W3003893050 hasAuthorship W3003893050A5086632008 @default.
• W3003893050 hasAuthorship W3003893050A5090756265 @default.
• W3003893050 hasBestOaLocation W30038930501 @default.
• W3003893050 hasConcept C104863432 @default.
• W3003893050 hasConcept C126322002 @default.
• W3003893050 hasConcept C177713679 @default.
• W3003893050 hasConcept C194828623 @default.
• W3003893050 hasConcept C195910791 @default.
• W3003893050 hasConcept C2776301958 @default.
• W3003893050 hasConcept C2778661090 @default.
• W3003893050 hasConcept C2779161974 @default.
• W3003893050 hasConcept C36434225 @default.
• W3003893050 hasConcept C512399662 @default.
• W3003893050 hasConcept C71924100 @default.
• W3003893050 hasConceptScore W3003893050C104863432 @default.
• W3003893050 hasConceptScore W3003893050C126322002 @default.
• W3003893050 hasConceptScore W3003893050C177713679 @default.
• W3003893050 hasConceptScore W3003893050C194828623 @default.
• W3003893050 hasConceptScore W3003893050C195910791 @default.
• W3003893050 hasConceptScore W3003893050C2776301958 @default.
• W3003893050 hasConceptScore W3003893050C2778661090 @default.
• W3003893050 hasConceptScore W3003893050C2779161974 @default.
• W3003893050 hasConceptScore W3003893050C36434225 @default.
• W3003893050 hasConceptScore W3003893050C512399662 @default.
• W3003893050 hasConceptScore W3003893050C71924100 @default.
• W3003893050 hasFunder F4320319990 @default.
• W3003893050 hasIssue "1" @default.
• W3003893050 hasLocation W30038930501 @default.
• W3003893050 hasLocation W30038930502 @default.
• W3003893050 hasLocation W30038930503 @default.
• W3003893050 hasLocation W30038930504 @default.
• W3003893050 hasLocation W30038930505 @default.
• W3003893050 hasLocation W30038930506 @default.
• W3003893050 hasOpenAccess W3003893050 @default.
• W3003893050 hasPrimaryLocation W30038930501 @default.

• next